Literature DB >> 1835931

Unaltered insulin sensitivity during calcium channel blockade with amlodipine.

P Ferrari1, D Giachino, P Weidmann, S Shaw, W Riesen, N Neuner, U Keller, G Heynen.   

Abstract

The sensitivity of peripheral tissues to insulin is of pathophysiological, therapeutic and possibly also of prognostic relevance. Calcium channel blockers are widely used in the treatment of cardiovascular disorders that are commonly associated with decreased insulin sensitivity (SI). To evaluate the effects of calcium channel blokkade on SI, glucose homoeostasis and lipid profiles, studies were made of SI (determined by the Minimal Model Method of Bergman), basal glucose and insulin levels, serum total triglyceride (Tg) and lipoprotein cholesterol (C) fractions and certain other variables in 38 healthy young men (24 y) during placebo and after 3 weeks of calcium channel blockade with amlodipine 5 mg once daily. Measurements were made after 3 days on a standard diet (2200 kcal.day-1, 45% carbohydrates, 40% fat and 15% proteins) and after an overnight fast. Compared to placebo, amlodipine decreased supine systolic blood pressure (P less than 0.01). Heart rate, body weight and 24 h urinary sodium excretion were unaltered, and so were fasting plasma glucose (placebo vs amlodipine: 4.86 vs 4.83 mmol.l-1, respectively) and insulin levels (7.7 vs 7.9 microU.ml-1), SI (10.5 vs 9.6.10(-4) x min-1 pro microU.ml-1), serum total Tg, C and lipoprotein C fractions. The findings demonstrate unchanged insulin sensitivity and secretion, as well as lipoprotein regulation, during maintenance administration of 5 mg amlodipine daily to healthy young men.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1835931     DOI: 10.1007/BF00265901

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  28 in total

1.  The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily.

Authors:  J K Faulkner; D McGibney; L F Chasseaud; J L Perry; I W Taylor
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

2.  Coated charcoal immunoassay of insulin.

Authors:  V Herbert; K S Lau; C W Gottlieb; S J Bleicher
Journal:  J Clin Endocrinol Metab       Date:  1965-10       Impact factor: 5.958

3.  Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 9 1/2-year follow-up of the Helsinki Policemen Study population.

Authors:  K Pyörälä; E Savolainen; S Kaukola; J Haapakoski
Journal:  Acta Med Scand Suppl       Date:  1985

Review 4.  Insulin, insulin sensitivity and hypertension.

Authors:  P Ferrari; P Weidmann
Journal:  J Hypertens       Date:  1990-06       Impact factor: 4.844

5.  Increased serum low-density lipoprotein cholesterol in men treated short-term with the diuretic chlorthalidone.

Authors:  Z Glück; P Weidmann; R Mordasini; C Bachmann; W Riesen; E Peheim; G Keusch; A Meier
Journal:  Metabolism       Date:  1980-03       Impact factor: 8.694

6.  Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp.

Authors:  R N Bergman; R Prager; A Volund; J M Olefsky
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

7.  The insulin sensitivity index in nondiabetic man. Correlation between clamp-derived and IVGTT-derived values.

Authors:  J C Beard; R N Bergman; W K Ward; D Porte
Journal:  Diabetes       Date:  1986-03       Impact factor: 9.461

8.  Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes.

Authors:  M R Taskinen; T Kuusi; E Helve; E A Nikkilä; H Yki-Järvinen
Journal:  Arteriosclerosis       Date:  1988 Mar-Apr

9.  Relationship between insulin resistance, insulin secretion, very low density lipoprotein kinetics, and plasma triglyceride levels in normotriglyceridemic man.

Authors:  T A Tobey; M Greenfield; F Kraemer; G M Reaven
Journal:  Metabolism       Date:  1981-02       Impact factor: 8.694

10.  Impairment of insulin secretion in man by nifedipine.

Authors:  D Giugliano; R Torella; F Cacciapuoti; S Gentile; M Verza; M Varricchio
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953

View more
  4 in total

1.  Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension.

Authors:  M de Courten; P Ferrari; M Schneider; L Böhlen; S Shaw; W Riesen; G Heynen; P Weidmann
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 2.  Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease.

Authors:  M Haria; A J Wagstaff
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

Review 3.  Insulin resistance and hypertension in the elderly. Optimal drug therapy.

Authors:  G Paolisso; A Gambardella; D Galzerano; M Varricchio
Journal:  Drugs Aging       Date:  1994-05       Impact factor: 3.923

4.  Direct renin inhibition modulates insulin resistance in caveolin-1-deficient mice.

Authors:  Somlak Chuengsamarn; Amanda E Garza; Alexander W Krug; Jose R Romero; Gail K Adler; Gordon H Williams; Luminita H Pojoga
Journal:  Metabolism       Date:  2012-09-04       Impact factor: 8.694

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.